Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

stethoscope and clipboard via Shutterstock
2040

Rate of non-melanoma skin cancer predicted to increase by over 350%

Incidents of cancer overall are expected to double according to figures from the National Cancer Registry.

THE NUMBER OF incidents of cancer in Ireland are expected to double by 2040, with some individual rates rising over 300 per cent.

The only fall in the figures, published this morning by the National Cancer Registry Ireland (NCRI), is in the rate of leukaemia in males of 57 per cent.

The NCRI predict that the rate of non-melanoma skin cancer will increase by by 235 per cent in females and 356 per cent in males.

This is a group of cancers that slowly develop in the upper layers of the skin, first appearing as a lump or patch on the skin that doesn’t heal.

A notable increase in incidents of lung cancer is also noted, with the rate rising faster in females, by 136 per cent.

The figures take into account population and demographic factors and trends in cancer rates since 1994.

The NCRI stressed that trends in female breast cancer and in prostate cancer “are difficult to predict”, but suggested that screening programmes for breast, cervical, and colorectal cancer will have an impact.

imageClick here to view a larger version. (Image: NCRI)

Read: Breast cancer patients who stop oral hormone therapy at threefold risk of recurrence >

Your Voice
Readers Comments
4
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.